Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes
Authors:
- Paul A DavisPDPaul A Davis
- Michelangelo SartoriMSMichelangelo Sartori
- Andrea SempliciniASAndrea Semplicini
- Achille C PessinaAPAchille C Pessina
- Lorenzo A CalLCLorenzo A Cal
- 1 October 2004
- journal article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 22 (10) , 1963-1969
Abstract
Angiotensin II (Ang II)-mediated activation of Rho kinase (ROK) is involved in the pathophysiology of hypertension and cardiovascular remodeling. ROK also controls plasminogen activator inhibitor-1 (PAI-1) which promotes vascular fibrosis contributing to atherogenesis. Bartter's and Gitelman's syndromes (BS/GS) are useful models to investigate abnormalities of vascular tone regulation, due to their reduced short- and long-term signaling pathways of Ang II. This study evaluated, using BS/GS as a model, ROK and PAI-1 gene and protein expression and the effect of Ang II co-incubation on ROK and PAI-1 gene and protein expression. We measured ROK and PAI-1 gene and protein expression [reverse transcription-polymerase chain reaction (RT-PCR) and Western blot] in mononuclear cells (PBM) from one BS and eight GS patients. The effect of Ang II on ROK and PAI-1 gene and protein expression was also evaluated and compared with 10 controls. ROK gene and protein expression was reduced in BS/GS [0.47 +/- 0.11 densitometric units (d.u.) versus 0.70 +/- 0.04 d.u., P = 0.0038 and 0.39 +/- 0.07 d.u. versus 0.55 +/- 0.07 d.u., P = 0.0026, respectively]. The basal level of PAI-1 gene and protein expression did not differ (0.40 +/- 0.03 d.u. versus 0.39 +/- 0.02 d.u. and 0.81 +/- 0.02 d.u. versus 0.83 +/- 0.02 d.u., respectively). Ang II increased ROK and PAI-1 gene and protein expression only in controls: from 0.70 +/- 0.04 to 0.90 +/- 0.06 d.u., P = 0.007 (ROK mRNA); from 0.55 +/- 0.07 to 0.86 +/- 0.07 d.u., P = 0.0005 (ROK protein); from 0.40 +/- 0.02 to 0.63 +/- 0.03 d.u., P = 0.001 (PAI-1 mRNA); and from 0.83 +/- 0.02 to 1.34 +/- 0.16 d.u., P = 0.0023 (PAI-1 protein). This study confirms BS/GS as a human model to investigate interrelated systems involved in the pathophysiology of hypertension and throws more light on the cellular mechanisms of BS/GS reduced Ang II short- and long-term signaling pathways.Keywords
This publication has 31 references indexed in Scilit:
- The role of RhoA and Rho-associated kinase in vascular smooth muscle contractionCurrent Hypertension Reports, 2003
- Important Role of Rho-kinase in the Pathogenesis of Cardiovascular Inflammation and Remodeling Induced by Long-Term Blockade of Nitric Oxide Synthesis in RatsHypertension, 2002
- Possible Involvement of Rho-Kinase in the Pathogenesis of Hypertension in HumansHypertension, 2001
- RhoA/Rho-kinase, vascular changes, and hypertensionCurrent Hypertension Reports, 2001
- Rho–Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cellsTrends in Pharmacological Sciences, 2001
- Involvement of Rho-Kinase in Angiotensin II–Induced Hypertrophy of Rat Vascular Smooth Muscle CellsHypertension, 2000
- Angiotensin II Activates RhoA in Cardiac MyocytesCirculation Research, 1998
- Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertensionNature, 1997
- Role of Rho GTPase in the Endothelin-1-Induced Nuclear SignalingBiochemical and Biophysical Research Communications, 1997
- A Novel Serine/Threonine Kinase Binding the Ras-related RhoA GTPase Which Translocates the Kinase to Peripheral MembranesJournal of Biological Chemistry, 1995